Fused and Substituted Piperazines as Anticancer Agents: A Review

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Pharmacology

Background:

• Cancer remains a significant health challenge, necessitating the development of safer and more effective anticancer drugs.
• Current limitations in anticancer therapies include toxicity to healthy cells and variable efficacy.
• The piperazine moiety is a versatile scaffold found in numerous biologically active compounds.

Purpose of the Study:

• To review recent advancements in the synthesis of fused and substituted piperazines.
• To explore the structure-activity relationships (SAR) of piperazine derivatives as anticancer agents.
• To summarize the mechanisms by which piperazine derivatives interact with biological targets for cancer treatment.

Main Methods:

• Literature review of recently published synthetic methodologies for piperazine derivatives.
• Analysis of SAR studies focusing on anticancer activity.
• Examination of reported molecular targets and receptor interactions of piperazine-based compounds.

Main Results:

• Piperazine derivatives exhibit diverse anticancer properties, including cell cycle inhibition (G1/S phase) and anti-angiogenic effects.
• The flexible binding nature of piperazine allows interaction with various biological targets.
• Recent synthetic strategies have expanded the repertoire of accessible piperazine structures.

Conclusions:

• Piperazine derivatives represent a promising class of compounds for anticancer drug development.
• Understanding SAR and target interactions is crucial for designing novel piperazine-based anticancer agents.
• This review provides valuable insights for medicinal chemists aiming to create more efficacious anticancer drugs with improved safety profiles.